Getting doctors to like biosimilars
This article was originally published in SRA
Executive Summary
Approving biosimilars is one thing; getting doctors to prescribe them is quite another. Usage of biosimilars is increasing in the EU, at least for some product classes, but it remains patchy, and while payers will welcome the cost savings biosimilars may bring, many physicians have yet to be convinced.